Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Plasma and antibody glycomic biomarkers of time to HIV rebound and viral setpoint.

Giron LB, Papasavvas E, Azzoni L, Yin X, Anzurez A, Damra M, Mounzer K, Kostman JR, Sanne I, Firnhaber CS, Tateno H, Liu Q, Montaner LJ, Abdel-Mohsen M.

AIDS. 2020 Jan 17. doi: 10.1097/QAD.0000000000002476. [Epub ahead of print]

PMID:
31972605
2.

NK Response Correlates with HIV Decrease in Pegylated IFN-α2a-Treated Antiretroviral Therapy-Suppressed Subjects.

Papasavvas E, Azzoni L, Kossenkov AV, Dawany N, Morales KH, Fair M, Ross BN, Lynn K, Mackiewicz A, Mounzer K, Tebas P, Jacobson JM, Kostman JR, Showe L, Montaner LJ.

J Immunol. 2019 Aug 1;203(3):705-717. doi: 10.4049/jimmunol.1801511. Epub 2019 Jun 28.

PMID:
31253727
3.

Determinants of Liver Complications Among HIV/Hepatitis B Virus-Coinfected Patients.

Lo Re V 3rd, Newcomb CW, Carbonari DM, Roy JA, Althoff KN, Kitahata MM, Reddy KR, Lim JK, Silverberg MJ, Mayor AM, Horberg MA, Cachay ER, Kirk GD, Hull M, Gill J, Sterling TR, Kostman JR, Peters MG, Moore RD, Klein MB, Kim HN; North American AIDS Cohort Collaboration on Research and Design of IeDEA.

J Acquir Immune Defic Syndr. 2019 Sep 1;82(1):71-80. doi: 10.1097/QAI.0000000000002094.

PMID:
31107304
4.

Listen to Your Heart.

Kostman JR.

JAMA. 2019 May 14;321(18):1769-1770. doi: 10.1001/jama.2019.5165. No abstract available.

PMID:
31087026
5.

Comparison of the prevalence, severity, and risk factors for hepatic steatosis in HIV-infected and uninfected people.

Torgersen J, So-Armah K, Freiberg MS, Goetz MB, Budoff MJ, Lim JK, Taddei T, Butt AA, Rodriguez-Barradas MC, Justice AC, Kostman JR, Lo Re V 3rd.

BMC Gastroenterol. 2019 Apr 15;19(1):52. doi: 10.1186/s12876-019-0969-1.

6.

Analytical antiretroviral therapy interruption does not irreversibly change preinterruption levels of cellular HIV.

Papasavvas E, Lada SM, Joseph J, Yin X, Liu Q, Azzoni L, Mounzer K, Kostman JR, Richman D, Montaner LJ.

AIDS. 2018 Aug 24;32(13):1763-1772. doi: 10.1097/QAD.0000000000001909.

7.

Absolute Insurer Denial of Direct-Acting Antiviral Therapy for Hepatitis C: A National Specialty Pharmacy Cohort Study.

Gowda C, Lott S, Grigorian M, Carbonari DM, Saine ME, Trooskin S, Roy JA, Kostman JR, Urick P, Lo Re V 3rd.

Open Forum Infect Dis. 2018 Jun 7;5(6):ofy076. doi: 10.1093/ofid/ofy076. eCollection 2018 Jun.

8.

CD32 is expressed on cells with transcriptionally active HIV but does not enrich for HIV DNA in resting T cells.

Abdel-Mohsen M, Kuri-Cervantes L, Grau-Exposito J, Spivak AM, Nell RA, Tomescu C, Vadrevu SK, Giron LB, Serra-Peinado C, Genescà M, Castellví J, Wu G, Del Rio Estrada PM, González-Navarro M, Lynn K, King CT, Vemula S, Cox K, Wan Y, Li Q, Mounzer K, Kostman J, Frank I, Paiardini M, Hazuda D, Reyes-Terán G, Richman D, Howell B, Tebas P, Martinez-Picado J, Planelles V, Buzon MJ, Betts MR, Montaner LJ.

Sci Transl Med. 2018 Apr 18;10(437). pii: eaar6759. doi: 10.1126/scitranslmed.aar6759.

9.

Risk of Acute Liver Injury After Statin Initiation by Human Immunodeficiency Virus and Chronic Hepatitis C Virus Infection Status.

Byrne DD, Tate JP, Forde KA, Lim JK, Goetz MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Bedimo R, Freiberg MS, Justice AC, Kostman JR, Roy JA, Lo Re V 3rd.

Clin Infect Dis. 2017 Oct 16;65(9):1542-1550. doi: 10.1093/cid/cix564.

10.

Risk of liver decompensation with cumulative use of mitochondrial toxic nucleoside analogues in HIV/hepatitis C virus coinfection.

Lo Re V Rd, Zeldow B, Kallan MJ, Tate JP, Carbonari DM, Hennessy S, Kostman JR, Lim JK, Goetz MB, Gross R, Justice AC, Roy JA.

Pharmacoepidemiol Drug Saf. 2017 Oct;26(10):1172-1181. doi: 10.1002/pds.4258. Epub 2017 Jul 19.

11.

Risk of Acute Liver Injury With Antiretroviral Therapy by Viral Hepatitis Status.

Gowda C, Newcomb CW, Liu Q, Carbonari DM, Lewis JD, Forde KA, Goldberg DS, Reddy KR, Roy JA, Marks AR, Schneider JL, Kostman JR, Tate JP, Lim JK, Justice AC, Goetz MB, Corley DA, Lo Re V.

Open Forum Infect Dis. 2017 Jan 28;4(2):ofx012. doi: 10.1093/ofid/ofx012. eCollection 2017 Spring.

12.

HCV viraemia associates with NK cell activation and dysfunction in antiretroviral therapy-treated HIV/HCV-co-infected subjects.

Papasavvas E, Azzoni L, Yin X, Liu Q, Joseph J, Mackiewicz A, Ross B, Lynn KM, Jacobson JM, Mounzer K, Kostman JR, Montaner LJ.

J Viral Hepat. 2017 Oct;24(10):865-876. doi: 10.1111/jvh.12714. Epub 2017 May 11.

13.

Prevalence and predictors of low muscle mass in HIV/viral hepatitis coinfection.

Gowda C, Brown TT, Compher C, Forde KA, Kostman J, Shaw PA, Tien PC, Lo Re V 3rd.

AIDS. 2016 Oct 23;30(16):2519-2528.

14.

Disparities in Absolute Denial of Modern Hepatitis C Therapy by Type of Insurance.

Lo Re V 3rd, Gowda C, Urick PN, Halladay JT, Binkley A, Carbonari DM, Battista K, Peleckis C, Gilmore J, Roy JA, Doshi JA, Reese PP, Reddy KR, Kostman JR.

Clin Gastroenterol Hepatol. 2016 Jul;14(7):1035-43. doi: 10.1016/j.cgh.2016.03.040. Epub 2016 Apr 5.

15.

Predicting Risk of End-Stage Liver Disease in Antiretroviral-Treated Human Immunodeficiency Virus/Hepatitis C Virus-Coinfected Patients.

Lo Re V 3rd, Kallan MJ, Tate JP, Lim JK, Goetz MB, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Park LS, Dubrow R, Reddy KR, Kostman JR, Justice AC, Localio AR.

Open Forum Infect Dis. 2015 Jul 9;2(3):ofv109. doi: 10.1093/ofid/ofv109. eCollection 2015 Sep.

16.

Access to Costly New Hepatitis C Drugs: Medicine, Money, and Advocacy.

Trooskin SB, Reynolds H, Kostman JR.

Clin Infect Dis. 2015 Dec 15;61(12):1825-30. doi: 10.1093/cid/civ677. Epub 2015 Aug 12. Review.

PMID:
26270682
17.

Correction for Patro et al., Shift in Monocyte Apoptosis with Increasing Viral Load and Change in Apoptosis-Related ISG/Bcl2 Family Gene Expression in Chronically HIV-1-Infected Subjects.

Patro SC, Pal S, Bi Y, Lynn K, Mounzer KC, Kostman JR, Davuluri RV, Montaner LJ.

J Virol. 2015 Jul;89(13):6970. doi: 10.1128/JVI.00735-15. No abstract available.

18.

Prevalence and risk factors for patient-reported joint pain among patients with HIV/hepatitis C coinfection, hepatitis C monoinfection, and HIV monoinfection.

Ogdie A, Pang WG, Forde KA, Samir BD, Mulugeta L, Chang KM, Kaplan DE, Amorosa VK, Kostman JR, Reddy RK, Schumacher RH, Lo Re V 3rd.

BMC Musculoskelet Disord. 2015 Apr 19;16:93. doi: 10.1186/s12891-015-0552-z.

19.

Structural Bone Deficits in HIV/HCV-Coinfected, HCV-Monoinfected, and HIV-Monoinfected Women.

Lo Re V 3rd, Lynn K, Stumm ER, Long J, Nezamzadeh MS, Baker JF, Hoofnagle AN, Kapalko AJ, Mounzer K, Zemel BS, Tebas P, Kostman JR, Leonard MB.

J Infect Dis. 2015 Sep 15;212(6):924-33. doi: 10.1093/infdis/jiv147. Epub 2015 Mar 9.

20.

Increased risk of hip fracture associated with dually treated HIV/hepatitis B virus coinfection.

Byrne DD, Newcomb CW, Carbonari DM, Nezamzadeh MS, Leidl KB, Herlim M, Yang YX, Hennessy S, Kostman JR, Leonard MB, Localio AR, Lo Re V 3rd.

J Viral Hepat. 2015 Nov;22(11):936-47. doi: 10.1111/jvh.12398. Epub 2015 Mar 6.

21.

Plasmacytoid dendritic cell and functional HIV Gag p55-specific T cells before treatment interruption can inform set-point plasma HIV viral load after treatment interruption in chronically suppressed HIV-1(+) patients.

Papasavvas E, Foulkes A, Yin X, Joseph J, Ross B, Azzoni L, Kostman JR, Mounzer K, Shull J, Montaner LJ.

Immunology. 2015 Jul;145(3):380-90. doi: 10.1111/imm.12452. Epub 2015 May 19.

22.

Shift in monocyte apoptosis with increasing viral load and change in apoptosis-related ISG/Bcl2 family gene expression in chronically HIV-1-infected subjects.

Patro SC, Pal S, Bi Y, Lynn K, Mounzer KC, Kostman JR, Davuluri RV, Montaner LJ.

J Virol. 2015 Jan;89(1):799-810. doi: 10.1128/JVI.02382-14. Epub 2014 Oct 29. Erratum in: J Virol. 2015 Jul;89(13):6970.

23.

A correlate of HIV-1 control consisting of both innate and adaptive immune parameters best predicts viral load by multivariable analysis in HIV-1 infected viremic controllers and chronically-infected non-controllers.

Tomescu C, Liu Q, Ross BN, Yin X, Lynn K, Mounzer KC, Kostman JR, Montaner LJ.

PLoS One. 2014 Jul 31;9(7):e103209. doi: 10.1371/journal.pone.0103209. eCollection 2014.

24.

Hepatic decompensation in antiretroviral-treated patients co-infected with HIV and hepatitis C virus compared with hepatitis C virus-monoinfected patients: a cohort study.

Lo Re V 3rd, Kallan MJ, Tate JP, Localio AR, Lim JK, Goetz MB, Klein MB, Rimland D, Rodriguez-Barradas MC, Butt AA, Gibert CL, Brown ST, Park L, Dubrow R, Reddy KR, Kostman JR, Strom BL, Justice AC.

Ann Intern Med. 2014 Mar 18;160(6):369-79. doi: 10.7326/M13-1829.

25.

Risk of hip fracture associated with untreated and treated chronic hepatitis B virus infection.

Byrne DD, Newcomb CW, Carbonari DM, Nezamzadeh MS, Leidl KB, Herlim M, Yang YX, Hennessy S, Kostman JR, Leonard MB, Localio AR, Lo Re V 3rd.

J Hepatol. 2014 Aug;61(2):210-8. doi: 10.1016/j.jhep.2014.04.001. Epub 2014 Apr 5.

26.

Prevalence of diagnosed chronic hepatitis B infection among U.S. Medicaid enrollees, 2000-2007.

Byrne DD, Newcomb CW, Carbonari DM, Nezamzadeh MS, Leidl KB, Herlim M, Yang YX, Hennessy S, Kostman JR, Leonard MB, Localio R, Lo Re V 3rd.

Ann Epidemiol. 2014 Jun;24(6):418-23. doi: 10.1016/j.annepidem.2014.02.013. Epub 2014 Mar 5.

27.

Incidence and risk factors for incomplete HBV DNA suppression in HIV/HBV-co-infected patients initiating tenofovir-based therapy.

Hafkin JS, Osborn MK, Localio AR, Amorosa VK, Kostman JR, Stern JJ, De La Torre P, Mounzer K, Frank I, Gross R, Chang KM, Lo Re V 3rd.

J Viral Hepat. 2014 Apr;21(4):288-96. doi: 10.1111/jvh.12142. Epub 2013 Jul 30.

28.

Improved treatment for primary HIV infection by interferon-alfa therapy? Does HCV treatment in HIV/HCV coinfected patients help us to test this hypothesis? Reply to zur Wiesch and van Lunzen.

Azzoni L, Foulkes AS, Papasavvas E, Mexas AM, Lynn KM, Mounzer K, Tebas P, Jacobson JM, Frank I, O'Doherty U, Kostman J, Montaner LJ.

J Infect Dis. 2013 Jul 15;208(2):363. doi: 10.1093/infdis/jit160. Epub 2013 Apr 9. No abstract available.

PMID:
23570845
29.

Willingness to undergo a repeat liver biopsy among HIV/hepatitis C virus-coinfected and hepatitis C virus-monoinfected patients.

Amorosa VK, Aibana O, Shire NJ, Dorey-Stein Z, Ferrara T, Gilmore J, Kostman JR, Lo Re V 3rd.

J Clin Gastroenterol. 2013 May-Jun;47(5):457-60. doi: 10.1097/MCG.0b013e318266fe70.

30.

Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration.

Azzoni L, Foulkes AS, Papasavvas E, Mexas AM, Lynn KM, Mounzer K, Tebas P, Jacobson JM, Frank I, Busch MP, Deeks SG, Carrington M, O'Doherty U, Kostman J, Montaner LJ.

J Infect Dis. 2013 Jan 15;207(2):213-22. doi: 10.1093/infdis/jis663. Epub 2012 Oct 26.

31.

Retinoblastoma protein induction by HIV viremia or CCR5 in monocytes exposed to HIV-1 mediates protection from activation-induced apoptosis: ex vivo and in vitro study.

Gekonge B, Raymond AD, Yin X, Kostman J, Mounzer K, Collman RG, Showe L, Montaner LJ.

J Leukoc Biol. 2012 Aug;92(2):397-405. doi: 10.1189/jlb.1111552. Epub 2012 Jun 13.

32.

Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/human immunodeficiency virus coinfection.

Lo Re V 3rd, Volk J, Newcomb CW, Yang YX, Freeman CP, Hennessy S, Kostman JR, Tebas P, Leonard MB, Localio AR.

Hepatology. 2012 Nov;56(5):1688-98. doi: 10.1002/hep.25866. Epub 2012 Oct 14.

33.

Pain and physical and psychological symptoms in ambulatory HIV patients in the current treatment era.

Merlin JS, Cen L, Praestgaard A, Turner M, Obando A, Alpert C, Woolston S, Casarett D, Kostman J, Gross R, Frank I.

J Pain Symptom Manage. 2012 Mar;43(3):638-45. doi: 10.1016/j.jpainsymman.2011.04.019. Epub 2011 Nov 23.

34.

Retention of functional DC-NK cross-talk following up to 18 weeks therapy interruptions in chronically suppressed HIV type 1+ subjects.

Papasavvas E, Chehimi J, Azzoni L, Pistilli M, Thiel B, Mackiewicz A, Creer S, Mounzer K, Kostman JR, Montaner LJ.

AIDS Res Hum Retroviruses. 2010 Oct;26(10):1047-9. doi: 10.1089/aid.2010.0020. Epub 2010 Aug 18. No abstract available.

35.

Increased metallothionein gene expression, zinc, and zinc-dependent resistance to apoptosis in circulating monocytes during HIV viremia.

Raymond AD, Gekonge B, Giri MS, Hancock A, Papasavvas E, Chehimi J, Kossenkov AV, Nicols C, Yousef M, Mounzer K, Shull J, Kostman J, Showe L, Montaner LJ.

J Leukoc Biol. 2010 Sep;88(3):589-96. doi: 10.1189/jlb.0110051. Epub 2010 Jun 15. Erratum in: J Leukoc Biol. 2010 Nov;88(5):1061. Kossevkov, Andrew V [corrected to Kossenkov, Andrew V]. J Leukoc Biol. 2010 Nov;88(5):1061a.

36.

Prevalence and risk factors for significant liver fibrosis among HIV-monoinfected patients.

DallaPiazza M, Amorosa VK, Localio R, Kostman JR, Lo Re V 3rd.

BMC Infect Dis. 2010 May 13;10:116. doi: 10.1186/1471-2334-10-116.

37.

The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients.

Amorosa VK, Slim J, Mounzer K, Bruno C, Hoffman-Terry M, Dorey-Stein Z, Ferrara T, Kostman JR, Lo Re V 3rd.

Antivir Ther. 2010;15(1):91-9. doi: 10.3851/IMP1492.

38.

Inability of plasmacytoid dendritic cells to directly lyse HIV-infected autologous CD4+ T cells despite induction of tumor necrosis factor-related apoptosis-inducing ligand.

Chehimi J, Papasavvas E, Tomescu C, Gekonge B, Abdulhaqq S, Raymond A, Hancock A, Vinekar K, Carty C, Reynolds G, Pistilli M, Mounzer K, Kostman J, Montaner LJ.

J Virol. 2010 Mar;84(6):2762-73. doi: 10.1128/JVI.01350-09. Epub 2009 Dec 30.

39.

HIV replication capacity is an independent predictor of disease progression in persons with untreated chronic HIV infection.

Goetz MB, Leduc R, Wyman N, Kostman JR, Labriola AM, Lie Y, Weidler J, Coakley E, Bates M, Luskin-Hawk R; Long Term Monitoring Study (CPCRA060) Terry Beirn Community Programs for Clinical Research on AIDS.

J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):472-9. doi: 10.1097/QAI.0b013e3181cae480.

40.

Viral hepatitis is associated with reduced bone mineral density in HIV-infected women but not men.

Lo Re V 3rd, Guaraldi G, Leonard MB, Localio AR, Lin J, Orlando G, Zirilli L, Rochira V, Kostman JR, Tebas P.

AIDS. 2009 Oct 23;23(16):2191-8. doi: 10.1097/QAD.0b013e32832ec258.

41.

Circulating monocytes in HIV-1-infected viremic subjects exhibit an antiapoptosis gene signature and virus- and host-mediated apoptosis resistance.

Giri MS, Nebozyhn M, Raymond A, Gekonge B, Hancock A, Creer S, Nicols C, Yousef M, Foulkes AS, Mounzer K, Shull J, Silvestri G, Kostman J, Collman RG, Showe L, Montaner LJ.

J Immunol. 2009 Apr 1;182(7):4459-70. doi: 10.4049/jimmunol.0801450.

42.

Evidence of a decrease in CD4 recovery once back on antiretroviral therapy after sequential > or =6 weeks antiretroviral therapy interruptions.

Papasavvas E, Foulkes A, Li X, Kostman JR, Mounzer KC, Montaner LJ.

J Acquir Immune Defic Syndr. 2009 Mar 1;50(3):334-5. doi: 10.1097/QAI.0b013e3181966b0c. No abstract available.

43.

Relationship between HIV coreceptor tropism and disease progression in persons with untreated chronic HIV infection.

Goetz MB, Leduc R, Kostman JR, Labriola AM, Lie Y, Weidler J, Coakley E, Bates M, Luskin-Hawk R; Long-Term Monitoring Study (CPCRA 060) and Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA).

J Acquir Immune Defic Syndr. 2009 Mar 1;50(3):259-66. doi: 10.1097/QAI.0b013e3181989a8b. Erratum in: J Acquir Immune Defic Syndr. 2009 May 1;51(1):110.

44.

Delayed loss of control of plasma lipopolysaccharide levels after therapy interruption in chronically HIV-1-infected patients.

Papasavvas E, Pistilli M, Reynolds G, Bucki R, Azzoni L, Chehimi J, Janmey PA, DiNubile MJ, Ondercin J, Kostman JR, Mounzer KC, Montaner LJ.

AIDS. 2009 Jan 28;23(3):369-75. doi: 10.1097/QAD.0b013e32831e9c76.

45.

Adherence to hepatitis C virus therapy and early virologic outcomes.

Lo Re V 3rd, Amorosa VK, Localio AR, O'Flynn R, Teal V, Dorey-Stein Z, Kostman JR, Gross R.

Clin Infect Dis. 2009 Jan 15;48(2):186-93. doi: 10.1086/595685.

46.

HIV type 1 viremia on ART is positively associated with polyclonal T cell proliferation in subjects with T cell IFN-gamma secretion levels comparable to those of uninfected subjects.

Papasavvas E, Moore EC, Sun J, Azzoni L, Pistilli M, Mounzer K, Shull J, Kostman JR, Montaner LJ.

AIDS Res Hum Retroviruses. 2008 Sep;24(9):1203-8. doi: 10.1089/aid.2008.0054.

47.

Management complexities of HIV/hepatitis C virus coinfection in the twenty-first century.

Lo Re V 3rd, Kostman JR, Amorosa VK.

Clin Liver Dis. 2008 Aug;12(3):587-609, ix. doi: 10.1016/j.cld.2008.03.009. Review.

48.
49.

Incidence of transaminitis among HIV-infected patients with occult hepatitis B.

Lo Re V 3rd, Wertheimer B, Localio AR, Kostman JR, Dockter J, Linnen JM, Giachetti C, Dorey-Stein Z, Frank I, Strom BL, Gross R.

J Clin Virol. 2008 Sep;43(1):32-6. doi: 10.1016/j.jcv.2008.03.030. Epub 2008 May 16.

50.

Severe weight gain, lipodystrophy, dyslipidemia, and obstructive sleep apnea in a human immunodeficiency virus-infected patient following highly active antiretroviral therapy.

Dorey-Stein Z, Amorosa VK, Kostman JR, Lo Re V 3rd, Shannon RP.

J Cardiometab Syndr. 2008 Spring;3(2):111-4. No abstract available.

Supplemental Content

Loading ...
Support Center